Hypoparathyroidism - Pipeline Review, H2 2012

Global Markets Direct, November 2012, Pages: 43

Hypoparathyroidism – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hypoparathyroidism - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hypoparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypoparathyroidism. Hypoparathyroidism - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypoparathyroidism.
- A review of the Hypoparathyroidism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hypoparathyroidism pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hypoparathyroidism.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hypoparathyroidism pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Hypoparathyroidism Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hypoparathyroidism 7
Hypoparathyroidism Therapeutics under Development by Companies 9
Hypoparathyroidism Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Hypoparathyroidism Therapeutics – Products under Development by Companies 13
Hypoparathyroidism Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Hypoparathyroidism Therapeutics Development 15
NPS Pharmaceuticals, Inc. 15
Rhein-Minapharm Biogenetics 16
Hypoparathyroidism – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
teriparatide - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Recombinant Human Parathyroid Hormone - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
teriparatide - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Parathyroid Hormone - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
teriparatide - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PTH (1-84) - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Hypoparathyroidism Therapeutics – Drug Profile Updates 30
Hypoparathyroidism – Product Development Milestones 32
Featured News & Press Releases 32
Oct 15, 2012: NPS Pharma Announces New Data From REPLACE Study Show Initiation Of Bone Remodeling For Natpara-Treated Patients With Hypoparathyroidism 32
Sep 05, 2012: NPS Pharma Expects To File Natpara BLA In Mid-2013 34
Jun 25, 2012: NPS Pharma Presents New Findings From REPLACE Study Of Natpara At ENDO 2012 Annual Meeting 34
Jun 18, 2012: NPS Pharma Reports Natpara Phase III Results To Be Presented At ENDO 2012 36
Nov 07, 2011: NPS Pharmaceuticals Announces Positive Top-Line Results From Pivotal Phase III REPLACE Study Of NPSP558 In Hypoparathyroidism 37
Sep 16, 2011: NPS Pharmaceuticals Highlights Hypoparathyroidism Data To Be Presented At Annual Meeting Of American Society For Bone And Mineral Research 38
Mar 01, 2011: NPS Pharmaceuticals Completes Patient Randomization In Phase III REPLACE Study Of NPSP558 In Hypoparathyroidism 39
Dec 22, 2008: NPS Pharmaceuticals Initiates Phase III 'REPLACE' Study Of NPSP558 In Hypoparathyroidism 40
Sep 15, 2008: Positive Interim Data From Phase II Study Of NPSP558 (Parathyroid Hormone 1-84) For Hypoparathyroidism Reported At ASBMR Annual Meeting 41
May 03, 2005: Abbott presents promising Zemplar (paricalcitol) capsules phase III data showing potential for earlier treatment of kidney disease complication 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Hypoparathyroidism, H2 2012 7
Products under Development for Hypoparathyroidism – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
NPS Pharmaceuticals, Inc., H2 2012 15
Rhein-Minapharm Biogenetics, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Hypoparathyroidism Therapeutics – Drug Profile Updates 30

List of Figures
Number of Products under Development for Hypoparathyroidism, H2 2012 7
Products under Development for Hypoparathyroidism – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21

Customers who bought this item also bought

• Drug Addiction – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Pipeline Review, H1 2013
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Liver Transplantation – Pipeline Review, H1 2013
• Peanut Allergy – Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Lung Infections – Pipeline Review, H1 2013